PHASE 2 STUDY OF ALDOXORUBICIN VERSUS TOPETECAN FOR RELAPSED/REFRACTORY SMALL CELL LUNG CANCER

被引：0
|
作者：
Wieland, S. [1 ]
Mita, A. [2 ]
Piantadosi, S. [2 ]
Natale, R. [2 ]
Levitt, D. [3 ]
机构：
[1] CytRx Corp, Clin Operat, Los Angeles, CA USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] CytRx Corp, Clin Dev, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu355.16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1478TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer
    Chiang, Anne C.
    Sequist, Lecia Van Dam
    Gilbert, Jill
    Conkling, Paul
    Thompson, Dana
    Marcoux, J. Paul
    Gettinger, Scott
    Kowanetz, Marcin
    Molinero, Luciana
    O'Hear, Carol
    Fasso, Marcella
    Lam, Sivuonthanh
    Gordon, Michael S.
    CLINICAL LUNG CANCER, 2020, 21 (05) : 455 - +
  • [32] Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer
    Mori, K
    Kamiyama, Y
    Kondo, T
    Kano, Y
    Kodama, T
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (01) : 86 - 90
  • [33] Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer
    Kiyoshi Mori
    Yukari Kamiyama
    Tetsuro Kondo
    Yasuhiko Kano
    Tetsuro Kodama
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 86 - 90
  • [34] A phase II study of nintedanib in patients with relapsed small cell lung cancer
    Han, Ji-Youn
    Kim, Hyae Young
    Lim, Kun Young
    Hwangbo, Bin
    Lee, Jin Soo
    LUNG CANCER, 2016, 96 : 108 - 112
  • [35] SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study
    Morgensztern, Daniel
    Johnson, Melissa
    Rudin, Charles M.
    Rossi, Michael
    Lazarov, Mirella
    Brickman, Daniel
    Fong, Abraham
    LUNG CANCER, 2020, 145 : 126 - 131
  • [36] Phase 2 Study of Irinotecan and Paclitaxel in Patients With Recurrent or Refractory Small Cell Lung Cancer
    Ramalingam, Suresh S.
    Foster, Judy
    Gooding, William
    Evans, Terry
    Sulecki, Matthew
    Belani, Chandra P.
    CANCER, 2010, 116 (05) : 1344 - 1349
  • [37] Phase II study of weekly cisplatin, etoposide and irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC).
    Kim, Y.
    Goto, K.
    Nishiwaki, Y.
    Kubota, K.
    Omatsu, H.
    Tamura, T.
    Ohe, Y.
    Kunitoh, H.
    Sekine, I.
    Yamamoto, N.
    Saijo, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 386S - 386S
  • [38] Doxorubicin and Topotecan for Relapsed/Refractory Small Cell Lung Cancer (SCLC): A FPBCC Clinical Trials Network Phase I Study
    Umakanthan, J. Manikkam
    Marr, A.
    Ernani, V.
    Kessinger, M.
    Smith, L.
    Tijerina, J.
    Radniecki, S.
    Kosmacek, E.
    Ketcham, M.
    Ganti, A. K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2188 - S2188
  • [39] Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer
    Hall, Peter E.
    Ready, Neal
    Johnston, Amanda
    Bomalaski, John S.
    Venhaus, Ralph R.
    Sheaff, Michael
    Krug, Lee
    Szlosarek, Peter W.
    CLINICAL LUNG CANCER, 2020, 21 (06) : 527 - 533
  • [40] Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients
    Kim, Gun Min
    Kim, Young Sam
    Kang, Young Ae
    Jeong, Jae-Heon
    Kim, Sun Mi
    Hong, Yun Kyoung
    Sung, Ji Hee
    Lim, Seung Taek
    Kim, Joo Hang
    Kim, Se Kyu
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (04) : 731 - 736
12345